CHF 0.00
In stock
SYN-1230-M0011 mgCHF 114.00
SYN-1230-M0055 mgCHF 213.00
SYN-1230-M01010 mgCHF 312.00
SYN-1230-M05050 mgCHF 1'064.00
SYN-1230-M100100 mgINQ
More Information
Product Details
Synonyms (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; BYL719; NVP-BYL719
Product Type Chemical
Formula C19H22F3N5O2S
MW 441.5
CAS 1217486-61-7
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO or DMF.
Declaration Manufactured by SynKinase.
Other Product Data Target: PI3Kalpha | Kinase Group: Lipid Kinase | Substrate: Lipid
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Selective PI3Kα inhibitor with IC50 of 5nM. Has minimal effect on other PI3K isoforms. Exhibits favorable pharmacokinetics and excellent oral bioavailability in animal models. In xenografts using nude mice, it showed dose-dependent effects of tumour inhibition. In a phase Ib study, it showed synergistic anti-tumor activity with endocrine therapy against ER+/PIK3CA mutated breast cancer cells.
Product References
  1. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation: P. Furet, et al.; Bioorg. Med. Chem. Lett. 23, 3741 (2013)
  2. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials: C. Fritsch, et al.; Mol. Cancer Ther. 13, 1117 (2014)
  3. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-specific Inhibitor, with Letrozole in ER+/HER2-Negative Metastatic Breast Cancer: I.A. Mayer, et al.; Clin. Cancer Res. (Epub ahead of print) (2016)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.